Sygnature Discovery

About Sygnature Discovery

At Sygnature Discovery, a global drug discovery CRO, we create exceptional scientific outcomes. For our customers, who bring life-changing medicines to patients; and for our people, who help make this possible. We’re 700+ scientists from over 50 countries, working as one across Europe and North America. With no competing internal programs, we offer total confidentiality and commitment. Over the past 20 years, we’ve earned a track record of real impact: 60+ advanced candidates, 200+ patents filed, 200+ active projects. Over 90% of our customers choose to stay with us – from biotechs racing to clinic to pharma companies that need specialised expertise for targeted challenges. We go Beyond Boundaries to deliver speed without compromising on quality. Founded in 2004, we have delivered over 40 pre-clinical compounds, 21 clinical compounds, and our scientists are named on over 170 patent applications. We partner with global pharma, biotech, and NFP organizations, providing integrated drug discovery services from target identification through to candidate nomination. Our co-located teams are experts in protein science, chemistry, computational chemistry, in vitro biology, pharmacology, DMPK, form and formulation services, and project management, with a core therapeutic focus on oncology, inflammation and immunology, as well as neuroscience, metabolic diseases, respiratory, infectious diseases and fibrotic diseases.